Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 67 O17 | DOI: 10.1530/endoabs.67.O17

1Department of Endocrinology, Centre of Postgraduate Medical Eduation, Bielanski Hospital, Warsaw, Poland; 2Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland; 3Department of Systemic Connective Tissue Diseases, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland; 4Department of Rheumatology, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.


Objective: Previous studies indicated that two glucocorticoid receptor gene polimorphisms bclI and N363S (GC-S) are associated with increased sensitivity to glucocorticoids and two other polymorphisms 9β and ER22/23EK (GC-I) are related to decreased sensitivity to glucocorticoids. The aim of the study was to determine whether these genetic changes can effect on the occurence of steroid-induced adverse events.

Methods: One hundred and fifty patients treated with glucocorticoids for over 3 months due to connective-tissue disease underwent clinical and biochemical evaluation. Genotyping of polymorphisms was carried out using a high resolution post PCR method that analyzes High Resolution Melting profiles. Analysis was performed comparing adverse effects of GCS treatment in carriers of GC-S or GC-I polymorphisms vs noncarriers.

Results: There was no significant difference in age, time of treatment, current and cumulative dose of glucocorticoids, BMI, waist circumference, bone mineral density, lean and fat mass, HOMA-IR, HbA1c, Matsuda Index, lipid profile, insulin or glucose concentration in OGTT or presence of adverse events of glucocorticoid treatment, including arterial hypertension, CVD, diabetes, osteopenia/osteoporosis and ‘Cushingoid appearence’ between GC-S carriers (n=74) vs noncarriers (n=76). GC-I carriers (n=46) had higher median cumulative dose of treatment (18.4 g vs 11.8 g, P=0.03) and there was higher prevalence of osteopenia/osteoporosis in this group comparing to GC-I noncarriers (n=104). There was no significance in other analyzed parameters.

Conclusions: The results of the present study show that there is no impact of glucocorticoid receptor polymorphisms on occurrence of steroid-induced adverse effects. Higher prevalence of osteopenia/osteoporosis in GC-I carriers is probably related to higher cumulative dose of glucocorticoids.

Volume 67

7th ESE Young Endocrinologists and Scientists (EYES) Meeting

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.